Sharemaestro company-news research for H. Lundbeck A/S (HLUN-B), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
CPH
Denmark
Insufficient evidence
Company news sentiment
Latest HLUN-B news and sentiment
H. Lundbeck A/S
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
MT Newswires · 30 Sep 2026 12:13
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
3 current stories are mapped specifically to HLUN-B.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news3 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
08 Sep23 Sep07 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness23
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202650DKK 43.68-3.5%
11 Sep 202650DKK 44.419998+0.7%
04 Sep 202650DKK 44.119999+6.5%
28 Aug 202651DKK 41.419998+0.9%
21 Aug 202652DKK 41.040001-3.5%
14 Aug 202650DKK 42.52+2.3%
07 Aug 202650DKK 41.580002+0.2%
31 Jul 202650DKK 41.5-1.5%
Insufficient evidence
News subjects
What is shaping the score
Deals and strategy501 stories · 33%
Market update501 stories · 33%
Regulatory and legal501 stories · 33%
Source mix
Where the evidence comes from
MT Newswires501 stories · 33%
Investing.com501 stories · 33%
Simply Wall St.501 stories · 33%
Recurring subjects
Subjects appearing most often
Share Price1Regulation1Pharma1Neuroscience1M A1Growth1Cns1Biotech1Balance Sheet1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
26 Jun50 neutral30 Sep 23:59
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 30 Sep 23:59 | 50 | +0 | 0/100 (0) | 3 (+1) | Insufficient |
| 29 Sep 23:59 | 50 | +0 | 0/100 (0) | 2 (+1) | Insufficient |
| 28 Sep 23:59 | 50 | -3 | 0/100 (-32) | 1 (-2) | Insufficient |
| 19 Aug 23:59 | 53 | +3 | 32/100 (+18) | 3 (-2) | Provisional |
| 05 Aug 23:59 | 50 | -1 | 14/100 (-3) | 5 (-2) | Provisional |
| 24 Jul 23:59 | 51 | -2 | 17/100 (-11) | 7 (+1) | Provisional |
| 18 Jul 23:59 | 53 | +1 | 28/100 (0) | 6 (+1) | Provisional |
| 15 Jul 23:59 | 52 | +1 | 28/100 (+10) | 5 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 3 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Deals and strategyNot used in direction
Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 12:13
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.4d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports
Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The Danish pharmaceutical group has been working with…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The Danish pharmaceutical group has been working with financial advisers to explore an acquisition of the U.S. firm, though discussions remain preliminary and may not result in a formal transaction. Still guessing which names to buy? Our AI rebuilds its stock picks at the start of every month. The list is beating the market by 120%. See what's on it » Shares of
- Published
- 29 Sep 2026 20:17
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechM APharma
—Unscored
Regulatory and legalNot used in direction
Can H. Lundbeck (CPSE:HLUN B) Look Cheap On Japan Eptinezumab Approval?
H. Lundbeck (CPSE:HLUN B) has just secured Japanese marketing authorization for eptinezumab in migraine prevention, a fresh regulatory milestone that broadens its neuroscience footprint and adds another data point for investors watching the stock. The eptinezumab approval lands at a time …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
H. Lundbeck (CPSE:HLUN B) has just secured Japanese marketing authorization for eptinezumab in migraine prevention, a fresh regulatory milestone that broadens its neuroscience footprint and adds another data point for investors watching the stock. The eptinezumab approval lands at a time when H. Lundbeck's recent news flow also includes the randomization milestone in its Phase III bexicaserin epilepsy program and a plan to shift its US base to Greater Boston to build out a global innovation hub. Investors have reacted positively in the short term, with a 1-day share price return of 3.71% and a
- Published
- 28 Sep 2026 09:07
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetCnsGrowthNeuroscienceRegulationShare Price
Earlier company news
HLUN-B news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 9 older HLUN-B headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to HLUN-B, but the headline and available text are not mainly about H. Lundbeck A/S. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of HLUN-B sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.